John has been covering financial markets since before the FTSE 100 existed, starting out on the Industries and Commodities team at Dun & Bradstreet, before moving on to Datastream, where he was head of the news team for several years. After a succession of management roles at Thomson Reuters he returned to front-line journalism in 2006. Prior to joining Proactive Investors he was managing editor at Sharecast.
The current annual refundable tax offset under Australia's research & development program is 43.5%.
Besides antibody lead generation, Dutch biotech ModiQuest also provides extensive antibody development and optimization procedures,
Solid has halted enrollment and dosing in IGNITE DMD and is awaiting the formal Clinical Hold letter from the FDA to understand the requirements for resuming the clinical trial
Amryt's lead drug candidate, AP101, is a potential treatment for epidermolysis bullosa, a rare genetic skin disorder for which there is currently no approved treatment
Dr Phillips's successor as CEO will be COO Dr Craig Cook, who has more than 20 years of international experience in the pharmaceutical, biomedical and high technology sectors
The recently announced positive interim data from PhaseOut DMD showed that after 24 weeks of treatment, there was a significant and meaningful reduction in muscle damage, as well as a significant reduction in muscle inflammation, in patients treated with ezutromid
CEO Andy Thorburn is focused for now on improving underlying operating procedures and performance, including a focus on the replacement GP systems contract for England, now perhaps 15-18 months away
Summit is extending an invitation to DMD sufferers who participated in the Phase 1 trial of ezutromid but who were not initially eligible for the Phase II trial to get back in the programme
A lot of academic research suggests a momentum investing strategy outperforms the market. John Harrington attempts to concoct a lazy person's momentum investing system.
A 31.4% gain in just over three months has given a respectable sheen to the performance of the virtual portfolio that is focused on dividend-paying growth stocks
Since the "bombed out" virtual portfolio bit the dust, we've lacked a stock filter that identifies recovery stocks; once again drawing on the simple ideas of Michael O'Higgins ("Dogs of the Dow"), John Harrington takes a look at the price-to-sales ratio as a means of identifying comeback kings.
The two most recent additions to the portfolio did the business at the tail end of 2017, but Zytronic gets the heave-ho on concerns over debt collection